Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CVT-427 in Healthy Adults
NCT02609945Phase 1Completed
- Sponsor
- Acorda Therapeutics
- Start
- Nov 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CVT-427 in migraine, sponsored by Acorda Therapeutics. Primary endpoints: Number of patients with adverse events (AEs) including serious AEs up to 23 days, Pulmonary function and 4 more. Started Nov 2015; status: completed.
02
Drugs
CVT-427
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02609945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609945.